A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein

被引:38
作者
Moran, O
Zegarra-Moran, O
机构
[1] CNR, Inst Biofis, I-16149 Genoa, Italy
[2] Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy
关键词
cystic fibrosis; chloride transport; nucleotide binding domain;
D O I
10.1016/j.febslet.2005.06.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The CFTR, encoded by the gene mutated in cystic fibrosis (CF) patients, is responsible for cAMP dependent chloride transport in epithelia. Substances that activate CFTR have been suggested as possible CF therapy. Most substances investigated so far exert a dual effect on the CFTR: low concentrations stimulate CFTR, whereas higher concentrations inhibit CFTR. Besides, the CFTR phosphorylation level determines the apparent affinity of the drug. We have studied the properties of genistein, the well known CFTR potentiator, by measuring apical membrane current on epithelia formed by cells stably transfected with CFTR and stimulated with different concentrations of CPT-cAMP. We propose a quantitative model to describe the activatory and inhibitory effect of genistein, accounting also for the cAMP dependent activation. (c) 2005 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
引用
收藏
页码:3979 / 3983
页数:5
相关论文
共 25 条
[1]   Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents [J].
Ai, T ;
Bompadre, SG ;
Wang, XH ;
Hu, SH ;
Li, M ;
Hwang, TC .
MOLECULAR PHARMACOLOGY, 2004, 65 (06) :1415-1426
[2]  
Al-Nakkash L, 2001, J PHARMACOL EXP THER, V296, P464
[3]   Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel [J].
Becq, F ;
Mettey, Y ;
Gray, MA ;
Galietta, LJV ;
Dormer, RL ;
Merten, M ;
Métayé, T ;
Chappe, V ;
Marvingt-Mounir, C ;
Zegarra-Moran, O ;
Tarran, R ;
Bulteau, L ;
Dérand, R ;
Pereira, MMC ;
McPherson, MK ;
Rogier, C ;
Joffre, M ;
Argent, BE ;
Sarrouilhe, D ;
Kammouni, W ;
Figarella, C ;
Verrier, B ;
Gola, M ;
Vierfond, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) :27415-27425
[4]   OPERATIONAL MODELS OF PHARMACOLOGICAL AGONISM [J].
BLACK, JW ;
LEFF, P .
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1983, 220 (1219) :141-162
[5]   CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds [J].
Caci, E ;
Folli, C ;
Zegarra-Moran, O ;
Ma, TH ;
Springsteel, MF ;
Sammelson, RE ;
Nantz, MH ;
Kurth, MJ ;
Verkman, AS ;
Galietta, LJV .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2003, 285 (01) :L180-L188
[6]   Phloxine B interacts with the cystic fibrosis transmembrane conductance regulator at multiple sites to modulate channel activity [J].
Cai, ZW ;
Sheppard, DN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (22) :19546-19553
[7]   8-cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and Delta F508 mutant first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator [J].
Cohen, BE ;
Lee, G ;
Jacobson, KA ;
Kim, YC ;
Huang, Z ;
Sorscher, EJ ;
Pollard, HB .
BIOCHEMISTRY, 1997, 36 (21) :6455-6461
[8]  
GADSBY DC, 1999, PHYSIOL REV, V79, P77
[9]   Identification of CFTR activators and inhibitors: chance or design? [J].
Galietta, LJV ;
Moran, O .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (05) :497-503
[10]   Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds [J].
Galietta, LJV ;
Springsteel, MF ;
Eda, M ;
Niedzinski, EJ ;
By, K ;
Haddadin, MJ ;
Kurth, MJ ;
Nantz, MH ;
Verkman, AS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (23) :19723-19728